Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of SNVs on adverse reactions and survival in gefitinib-treated lung cancer patients from a preliminary study.

Scientific reports - 11 Feb 2026

Morau Mariana Vieira, Seguin Cecília Souto, Perroud Mauricio Wesley, Dagli-Hernandez Carolina, Fidelis Giovana Fernanda Santos, de Carvalho Pincinato Eder, Moriel Patricia

Abstract excerpt

Gefitinib is indicated for metastatic non-small cell lung cancer (NSCLC) with active mutations in the epidermal growth factor receptor (EGFR) gene; however, its use is frequently associated with dermatological, gastrointestinal, and hepatic adverse drug reactions (ADRs). This study investigated whether single-nucleotide variants (SNVs) in the EGFR, ABCB1, and ABCG2 influence gefitinib-related ADRs and survival in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to ATP Binding Cassette Transporter, Subfamily B

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to ATP Binding Cassette Transporter, Subfamily G, Member 2

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Gefitinib

Share to Lung Neoplasms

Share to Neoplasm Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 41667687
DOI: 10.1038/s41598-026-38707-0
PMCID: PMC12966475

Genes

ABCB1
EGFR
ABCG2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of SNVs on adverse reactions and survival in gefitinib-treated lung cancer patients from a preliminary study.PMID 41667687Read ↗

Genetic Variants in the ABCB1 and ABCG2 Gene Drug Transporters Involved in Gefitinib-Associated Adverse Reaction: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Influence of genetic polymorphisms on gefitinib pharmacokinetics and adverse drug reactions in non-small cell lung cancer patients.Semantic proximity Read ↗

Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters.Semantic proximity Read ↗

Polymorphisms of NF-κB pathway genes influence adverse drug reactions of gefitinib in NSCLC patients.Semantic proximity Read ↗

Genetic Association of Curative and Adverse Reactions to Tyrosine Kinase Inhibitors in Chinese advanced Non-Small Cell Lung Cancer patients.Semantic proximity Read ↗

Association of STAT3, CYP3A5, and ABCG2 Polymorphisms With Osimertinib-induced Adverse Events in NSCLC Patients.Semantic proximity Read ↗

Impact of ABCG2 rs2231142(421C>A) Variant on the Clinical Outcomes of Patients With EGFR-mutated Non-small Cell Lung Cancer Treated With Gefitinib: A Comprehensive Meta-analysis.Semantic proximity Read ↗

Safety of gefitinib in non-small cell lung cancer treatment.Semantic proximity Read ↗

Association of genetic polymorphisms of CYP3A4 and CYP2D6 with gefitinib-induced toxicities.Semantic proximity Read ↗

Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer.Semantic proximity Read ↗

A review on adverse event profiles of epidermal growth factor receptor-tyrosine kinase inhibitors in nonsmall cell lung cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.